The Bionic Devices Market is anticipated to be worth about US$ 11.90 billion by 2033, from US$ 6.22 billion in 2025, growing at a CAGR of 8.45% during 2025-2033. Key factors driving this expansion include technological advances in wearable robotics and prosthetics, rising chronic illnesses and disabilities, and an increasing demand for personalized and non-invasive medical treatments. Additionally, emerging artificial intelligence and material development and increased health expenditure are further expected to benefit patients and enhance devices' performance.
Bionic devices are the advanced technologies engineered to emulate or enhance the functions of biological limbs or organs. Many of them involve the integration of robotics, sensors, and artificial intelligence to restore or improve mobility and functionality in individuals with disabilities or limb loss. Common examples include prosthetic limbs that can emulate natural movement, cochlear implants for hearing, and even advanced exoskeletons that help individuals walk.
Bionic devices have surged in popularity across the globe due to increased awareness and rapid advancement in technology. As medical research evolves, such devices are continuously being manufactured to be more sophisticated, lighter in weight, and easier to use. With this rise in accessibility, a larger population is able to benefit from bionic solutions. In addition, an aging global population and a rise in conditions that require amputation have driven further growth into the marketplace.
The United States, Germany, and Japan have been in the lead of developments and deployments of bionic technologies, and subsequently, transformative impacts on rehabilitation and quality of life are being felt. As society embraces innovation in health, the future for bionics is promising, with hope being given to many around the world.
Founded: 1888
Abbott Laboratories is one of the leading medical device and healthcare companies that discovers, develops, manufactures, and sells diversified products in the world market. The business portfolio of Abbott consists of gastroenterology and women’s health, cardiovascular and metabolic health, pain management, central nervous system disorders, and many more. It also covers respiratory drugs and vaccines, biosimilars, core laboratory systems, and transfusion medicine technologies along with point-of-care systems. Its portfolio also comprises rapid diagnostic lateral flow tests, informatics and automation solutions, nutritional products, and rhythm management, electrophysiology, and heart failure-related devices. Its product portfolio encompasses a wide range of vascular and structural heart needs as well as neuromodulation therapies. Abbott undertakes to market its products primarily through wholesalers, distributors, government agencies, healthcare facilities, pharmacies, and retail buyers, among independent retailers. The company markets its products in North America, Latin America, the Middle East, Europe, the Asia-Pacific, and Africa.
Founded: 1958
Edwards Lifesciences Corp (Edwards Lifesciences) is a medical technology company. It develops, manufactures and markets devices for structural heart disease, critical care and surgical monitoring. The company's products comprise surgical valve repair devices, surgical valve replacement, hemodynamic monitoring devices, transcatheter heart valves, pressure monitoring devices, and related instruments and accessories. Its products find application for various therapies such as transcatheter aortic valve replacement (TAVR), blood conservation, infection control, enhanced surgical recovery, and for the management of clotting, hypotension and sepsis. The company markets products through a direct sales force and a network of independent distributors in North America, Europe and Asia-Pacific
Founded: 2001
Lifeward Inc (Lifeward), formerly ReWalk Robotics Ltd, is a medical device company that designs, develops and commercializes exoskeletons. The company offers walk restoration devices for people with lower limb disabilities to stand and walk once again. Its products include rewalk personal systems and ReWalk rehabilitation. Lifeward's rewalk personal system is a battery-powered system that controls movement using subtle changes in the center of gravity. The company’s Rewalk Rehabilitation is designed for clinics to provide exercise and therapy for patients. It serves medical equipment, rehabilitation centers, and healthcare sectors. The company operates in the US, Germany and Israel. Lifeward is headquartered in Yokne'am Illit, Israel.
Founded: 1979
Boston Scientific Corp (Boston Scientific) is a medical technology company that develops, manufactures, and commercializes devices for a range of interventional medical specialties. The company offers products in the areas of electrophysiology, gastroenterology, gastrointestinal surgery, female pelvic medicine, gynecology, interventional cardiology, interventional radiology, neurological surgery, orthopedic surgery, pain medicine, pulmonology, urology, and vascular surgery. Boston Scientific serves hospitals, clinics, outpatient facilities, and medical offices across the world. The company has manufacturing facilities in the US, Ireland, Costa Rica, Brazil, Malaysia, and Puerto Rico. It sells products directly and through a network of distributors and dealers in Europe, the Middle East, Africa, Asia Pacific, and the Americas.
The key strength of Ottobock SE & Co. KGaA in the bionic devices market is its century-long experience in leading innovation in prosthetics and orthotics, combining medical know-how with the most up-to-date mechatronics and biotechnology. Its strong R&D foundation has come up with revolutionary products such as the C-Leg, Genium X3, and Michelangelo Hand that set global standards for functional precision and user comfort. Ottobock's intimate knowledge in human biomechanics and rehabilitation medicine forms the basis for developing outstandingly adaptive bionic systems that return natural movement and independence to users. Extensive global distribution with clinical partnerships and personalized fitting services increases accessibility and trust in its brand. Moreover, Ottobock's focus on integrating more digital technologies, such as AI-based motion analysis and smart prosthetic control elements, cements its leading role in patient-oriented innovation. This combination of technological excellence, global reach, and clinical expertise makes Ottobock a benchmark in the evolving bionic mobility market.
Bionic devices are the advanced technologies engineered to emulate or enhance the functions of biological limbs or organs. Many of them involve the integration of robotics, sensors, and artificial intelligence to restore or improve mobility and functionality in individuals with disabilities or limb loss. Common examples include prosthetic limbs that can emulate natural movement, cochlear implants for hearing, and even advanced exoskeletons that help individuals walk.
Bionic devices have surged in popularity across the globe due to increased awareness and rapid advancement in technology. As medical research evolves, such devices are continuously being manufactured to be more sophisticated, lighter in weight, and easier to use. With this rise in accessibility, a larger population is able to benefit from bionic solutions. In addition, an aging global population and a rise in conditions that require amputation have driven further growth into the marketplace.
The United States, Germany, and Japan have been in the lead of developments and deployments of bionic technologies, and subsequently, transformative impacts on rehabilitation and quality of life are being felt. As society embraces innovation in health, the future for bionics is promising, with hope being given to many around the world.
Top 5 Companies in the Global Bionic Devices Market by 2033
Abbott Laboratories
Headquarters: United States of AmericaFounded: 1888
Abbott Laboratories is one of the leading medical device and healthcare companies that discovers, develops, manufactures, and sells diversified products in the world market. The business portfolio of Abbott consists of gastroenterology and women’s health, cardiovascular and metabolic health, pain management, central nervous system disorders, and many more. It also covers respiratory drugs and vaccines, biosimilars, core laboratory systems, and transfusion medicine technologies along with point-of-care systems. Its portfolio also comprises rapid diagnostic lateral flow tests, informatics and automation solutions, nutritional products, and rhythm management, electrophysiology, and heart failure-related devices. Its product portfolio encompasses a wide range of vascular and structural heart needs as well as neuromodulation therapies. Abbott undertakes to market its products primarily through wholesalers, distributors, government agencies, healthcare facilities, pharmacies, and retail buyers, among independent retailers. The company markets its products in North America, Latin America, the Middle East, Europe, the Asia-Pacific, and Africa.
Abiomed
Headquarters: United States of AmericaFounded:1981
Abiomed Inc is a medical device company. The company is involved in the design and development of heart pump technologies. The Impella family gives patients with severe coronary artery disease and heart failure temporary hemodynamic support. Its product pipeline includes Impella CP for high-risk PCI procedures and cardiogenic shock, and Impella 5.5, which provides full cardiac support over long durations. Impella RP supports patients with right heart failure. Abiomed offers the Breethe OXY-1 System, a compact cardiopulmonary support device featuring an integrated oxygenator that oxygenates and pumps blood while enabling patient mobility. The company also offers Impella Connect, a cloud-based platform that allows healthcare teams to remotely monitor patient status.Edward Lifesciences Corp.
Headquarters: United States of AmericaFounded: 1958
Edwards Lifesciences Corp (Edwards Lifesciences) is a medical technology company. It develops, manufactures and markets devices for structural heart disease, critical care and surgical monitoring. The company's products comprise surgical valve repair devices, surgical valve replacement, hemodynamic monitoring devices, transcatheter heart valves, pressure monitoring devices, and related instruments and accessories. Its products find application for various therapies such as transcatheter aortic valve replacement (TAVR), blood conservation, infection control, enhanced surgical recovery, and for the management of clotting, hypotension and sepsis. The company markets products through a direct sales force and a network of independent distributors in North America, Europe and Asia-Pacific
Rewalk Robotics Ltd.
Headquarters: IsraelFounded: 2001
Lifeward Inc (Lifeward), formerly ReWalk Robotics Ltd, is a medical device company that designs, develops and commercializes exoskeletons. The company offers walk restoration devices for people with lower limb disabilities to stand and walk once again. Its products include rewalk personal systems and ReWalk rehabilitation. Lifeward's rewalk personal system is a battery-powered system that controls movement using subtle changes in the center of gravity. The company’s Rewalk Rehabilitation is designed for clinics to provide exercise and therapy for patients. It serves medical equipment, rehabilitation centers, and healthcare sectors. The company operates in the US, Germany and Israel. Lifeward is headquartered in Yokne'am Illit, Israel.
Boston Scientific Corp.
Headquarters: United States of AmericaFounded: 1979
Boston Scientific Corp (Boston Scientific) is a medical technology company that develops, manufactures, and commercializes devices for a range of interventional medical specialties. The company offers products in the areas of electrophysiology, gastroenterology, gastrointestinal surgery, female pelvic medicine, gynecology, interventional cardiology, interventional radiology, neurological surgery, orthopedic surgery, pain medicine, pulmonology, urology, and vascular surgery. Boston Scientific serves hospitals, clinics, outpatient facilities, and medical offices across the world. The company has manufacturing facilities in the US, Ireland, Costa Rica, Brazil, Malaysia, and Puerto Rico. It sells products directly and through a network of distributors and dealers in Europe, the Middle East, Africa, Asia Pacific, and the Americas.
Product Launches in the Bionic Devices Market
Pixium Vision SA
March 2023 | Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX) is a bioelectronics company that develops innovative bionic vision systems intended to enable patients who have lost their sight to lead more independent lives. Today, the company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its Prima System. This system is a photovoltaic substitute for photoreceptors, providing the ability to use simultaneously a central prosthetic and peripheral natural vision in patients with atrophic dry age-related macular degeneration (AMD), aiming to partially restore their vision.Cochlear Limited
July 2025, Cochlear Limited, the global leader in implantable hearing solutions, has announced the approval of the Cochlear™ Nucleus® Nexa™ System by the U.S. Food and Drug Administration (FDA). This system is the world’s first and only smart cochlear implant. Until now, recipients of cochlear implants have been limited to accessing new technology through the external component, known as the sound processor. Typically, to fully benefit from new technologies, users would need to obtain a new sound processor. The Nexa System introduces upgradeable implant firmware, allowing Cochlear recipients to access future innovations through both their implant and sound processor for the first time. This new pathway for firmware updates will enhance sound processor upgrades, ensuring recipients can experience optimal hearing and have greater access to new advancements over time.SWOT Analysis of Company in the Bionic Devices Market
EKSO Bionics Holdings Inc.
Strength - Technological Leadership in Wearable Exoskeleton Innovation
The greatest strength of Ekso Bionics Holdings Inc. in the field of bionic devices is its pioneering technological resource and leading position in the development of sophisticated wearable exoskeletons for medical, industrial, and defense applications. Its deep R&D capabilities have empowered the development of high-performance, human-augmenting systems like EksoNR and EksoVest, enhancing mobility, rehabilitation, and physical fortitude. With its strong foundation in robotics, biomechanics, and human-machine integration, Ekso Bionics offers precise, adaptive solutions in support of stroke and spinal cord injury rehabilitation, while improving workplace safety and productivity. Strategic partnerships with leading healthcare institutions, rehabilitation centers, and industrial enterprises further strengthen Ekso's innovation ecosystem and market credibility. With a portfolio built on patented technologies and clinical validation, Ekso Bionics sustains competitiveness, positioned as a trusted leader in progressing human mobility and functional recovery by intelligent bionic engineering.Ottobock SE & Co. KGaA
Strength: Global Leadership in Prosthetics and Human Mobility SolutionsThe key strength of Ottobock SE & Co. KGaA in the bionic devices market is its century-long experience in leading innovation in prosthetics and orthotics, combining medical know-how with the most up-to-date mechatronics and biotechnology. Its strong R&D foundation has come up with revolutionary products such as the C-Leg, Genium X3, and Michelangelo Hand that set global standards for functional precision and user comfort. Ottobock's intimate knowledge in human biomechanics and rehabilitation medicine forms the basis for developing outstandingly adaptive bionic systems that return natural movement and independence to users. Extensive global distribution with clinical partnerships and personalized fitting services increases accessibility and trust in its brand. Moreover, Ottobock's focus on integrating more digital technologies, such as AI-based motion analysis and smart prosthetic control elements, cements its leading role in patient-oriented innovation. This combination of technological excellence, global reach, and clinical expertise makes Ottobock a benchmark in the evolving bionic mobility market.
Recent Development in Global Bionic Devices Market
Medtronic Plc
In February of 2025, Medtronic announced the U.S. FDA approval of the world's first closed-loop aDBS system for Parkinson's disease. This device automatically adjusts stimulation in real-time based on individual brain activity-a first-to-market advance in the treatment of movement disorders. The technology was also named one of TIME's Best Inventions of 2025.William Demant Holdings A/S
Demant announced and expects to complete the acquisition of the German hearing care retail chain KIND Group for €700 million in the second half of 2025. This acquisition is a major strategic move to secure a leading position in the German hearing care market, adding around 600 clinics in Germany, Switzerland, Austria, Luxembourg, and Singapore.Sustainability Goals in Global Bionic Devices Market
Sonova Holding AG
Sonova Holding AG's sustainability vision aims at long-term value creation by combining innovative hearing solutions with environmental stewardship and social responsibility. This includes pursuing carbon-neutral operations through further energy efficiency optimization, increased renewable energy sources, and decreased GHG emissions at productions and within supply chains. Sonova advances sustainable product design, focusing on durability, recyclability, and minimization of waste across the life cycle of products. Socially, it fosters inclusion through international hearing health programs, striving to give people in need access to hearing care worldwide through its Hear the World Foundation. Employee engagement, diversity, and ethical governance form key pillars of the company's sustainability vision. Through integrating environmental, social, and economic goals, Sonova seeks to provide sustainable innovation that will improve the quality of life for millions of people while preserving the planet: making sure better hearing goes together with a better future.Bionik Laboratories Corp.
Bionik Laboratories Corp.'s sustainability objective is focused on enhancing human mobility through robotics and assistive technology, coupled with a commitment to environmental responsibility, ethical business operations, and social accountability. In that regard, the company pursues creating long-lasting, efficient rehabilitation and mobility devices that are waste-efficient and conserve natural resources throughout their life cycle. Considerations of sustainability within product design help Bionik develop long-lasting robotic systems that reduce hospital maintenance costs and minimize environmental impact. The firm also places emphasis on responsible sourcing, lean manufacturing, and ethics in labor practices among its suppliers. Social sustainability is one of the corners of its operation, through which Bionik seeks to improve the quality of lives of patients recovering from neurological disorders with accessible, patient-centered solutions. It fosters an inclusive culture internally that values innovation, employee well-being, and diversity. All told, the vision of Bionik reflects a path toward aligning technological progress with global strides for a healthy, fair, and ecologically sensitive future.Market Segmentation
Bionic Devices Market
- Historical Trends
- Forecast Analysis
Market Share Analysis - Bionic Devices Market
Abbott Laboratories
Overview
- Company History and Mission
- Business Model and Operations
- Workforce
Key Persons
- Executive Leadership
- Operational Management
- Division Leaders
- Board Composition
Recent Development & Strategies
- Mergers & Acquisitions
- Partnerships
- Investments
Sustainability Analysis
- Renewable Energy Adoption
- Energy-Efficient Infrastructure
- Use of Sustainable Packaging Materials
- Water Usage and Conservation Strategies
- Waste Management and Circular Economy Initiatives
Product Analysis
- Product Profile
- Quality Standards
- Product Pipeline
- Product Benchmarking
Strategic Assessment: SWOT Analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
Revenue Analysis
The above information will be available for all the following companies:
- Abbott Laboratories
- Abiomed
- Edward Lifesciences Corp.
- Rewalk Robotics Ltd.
- Boston Scientific Corp.
- Baxter International Inc.
- Cochlear Ltd.
- Medtronic Plc,
- William Demant Holdings A/S
- EKSO Bionics Holdings Inc.
- Ottobock SE & Co. KGaA
- Sonova Holding AG
- Bionik Laboratories Corp.
- Pixium Vision SA
- Open Bionics Ltd.
- Cyberdyne Inc.
- Myomo, Inc.
Table of Contents
1. Bionic Devices Market
3. Abbott Laboratories
The above information will be available for all the following companies:
Companies Mentioned
- Abbott Laboratories
- Abiomed
- Edward Lifesciences Corp.
- Rewalk Robotics Ltd.
- Boston Scientific Corp.
- Baxter International Inc.
- Cochlear Ltd.
- Medtronic Plc,
- William Demant Holdings A/S
- EKSO Bionics Holdings Inc.
- Ottobock SE & Co. KGaA
- Sonova Holding AG
- Bionik Laboratories Corp.
- Pixium Vision SA
- Open Bionics Ltd.
- Cyberdyne Inc.
- Myomo, Inc.
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | December 2025 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 6.22 Billion |
| Forecasted Market Value ( USD | $ 11.9 Billion |
| Compound Annual Growth Rate | 8.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 17 |
